<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1180">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04283461</url>
  </required_header>
  <id_info>
    <org_study_id>20-0003</org_study_id>
    <secondary_id>1UM1AI148373-01</secondary_id>
    <nct_id>NCT04283461</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)</brief_title>
  <official_title>Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females,
      starting at 18 years of age, inclusive, who are in good health and meet all eligibility
      criteria. This clinical trial is designed to assess the safety, reactogenicity and
      immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid
      nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion
      stabilized spike (S) protein of SARS-CoV-2. Enrollment will occur at up to 3 domestic
      clinical research sites. One hundred and fifty-five subjects will be enrolled into one of
      thirteen cohorts (10 micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, and 250 mcg). Subjects will
      receive an intramuscular (IM) injection (0.5 milliliters [mL]) of mRNA-1273 on Days 1 and 29
      in the deltoid muscle and will be followed through 12 months post second vaccination (Day
      394). Follow-up visits will occur 1, 2, and 4 weeks post each vaccination (Days 8, 15, 29,
      36, 43, and 57), as well as 3, 6, and 12 months post second vaccination (Days 119, 209, and
      394). The primary objective is to evaluate the safety and reactogenicity of a 2-dose
      vaccination schedule of mRNA-1273, given 28 days apart, across 5 dosages in healthy adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females,
      starting at 18 years of age, inclusive, who are in good health and meet all eligibility
      criteria. This clinical trial is designed to assess the safety, reactogenicity and
      immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. mRNA-1273 is a novel lipid
      nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion
      stabilized spike (S) protein of SARS-CoV-2. Enrollment will occur at up to 3 domestic
      clinical research sites. One hundred and fifty-five subjects will be enrolled into one of
      thirteen cohorts (10 micrograms [mcg], 25 mcg, 50 mcg, 100 mcg, or 250 mcg). Subjects will
      receive an intramuscular (IM) injection (0.5 milliliters [mL]) of mRNA-1273 on Days 1 and 29
      in the deltoid muscle and will be followed through 12 months post second vaccination (Day
      394). Follow-up visits will occur 1, 2, and 4 weeks post each vaccination (Days 8, 15, 29,
      36, 43, and 57), as well as 3, 6, and 12 months post second vaccination (Days 119, 209, and
      394). The primary objective is to evaluate the safety and reactogenicity of a 2-dose
      vaccination schedule of mRNA-1273, given 28 days apart, across 5 dosages in healthy adults.
      The secondary objective is to evaluate the immunogenicity as measured by Immunoglobulin G
      (IgG) enzyme-linked immunosorbent assay (ELISA) to the SARS-CoV-2 S (spike) protein following
      a 2-dose vaccination schedule of mRNA-1273 at Day 57.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 16, 2020</start_date>
  <completion_date type="Anticipated">November 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 22, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of solicited local reactogenicity adverse events (AEs)</measure>
    <time_frame>Through 7 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of any medically-attended adverse events (MAAEs)</measure>
    <time_frame>Day 1 to Day 394</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of any new-onset chronic medical conditions (NOCMCs)</measure>
    <time_frame>Day 1 to Day 394</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of any serious adverse events (SAEs)</measure>
    <time_frame>Day 1 to Day 394</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of any unsolicited adverse events (AEs)</measure>
    <time_frame>Through 28 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of solicited systemic reactogenicity adverse events (AEs)</measure>
    <time_frame>Through 7 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of any unsolicited adverse events (AEs)</measure>
    <time_frame>Through 28 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of solicited local reactogenicity adverse events (AEs)</measure>
    <time_frame>Through 7 days post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade of solicited systemic reactogenicity adverse events (AEs)</measure>
    <time_frame>Through 7 days post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric mean fold rise (GMFR) in IgG titer from baseline</measure>
    <time_frame>Day 1 to Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean titer (GMT) of antibody</measure>
    <time_frame>Day 57</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who seroconverted</measure>
    <time_frame>Day 1 to Day 57</time_frame>
    <description>Seroconversion is defined as a 4-fold change in antibody titer from baseline</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>COVID-19</condition>
  <condition>COVID-19 Immunisation</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 12</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 13</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 18-55 years of age. N=15 (4 sentinel, 11 non-sentinel).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants from 56-70 years of age. N=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mcg of mRNA-1273 administered through 0.5 mL intramuscular injection in the deltoid muscle on Days 1 and 29 in participants 71 years of age or older. N=10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mRNA-1273</intervention_name>
    <description>Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. mRNA-1273 consists of an mRNA Drug Substance that is manufactured into LNPs composed of the proprietary ionizable lipid, SM-102, and 3 commercially available lipids, cholesterol, DSPC, and PEG2000 DMG.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 10</arm_group_label>
    <arm_group_label>Arm 11</arm_group_label>
    <arm_group_label>Arm 12</arm_group_label>
    <arm_group_label>Arm 13</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_label>Arm 5</arm_group_label>
    <arm_group_label>Arm 6</arm_group_label>
    <arm_group_label>Arm 7</arm_group_label>
    <arm_group_label>Arm 8</arm_group_label>
    <arm_group_label>Arm 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        A subject must meet all of the following criteria to be eligible to participate in this
        study:

          1. Provides written informed consent prior to initiation of any study procedures.

          2. Be able to understand and agrees to comply with planned study procedures and be
             available for all study visits.

          3. Agrees to the collection of venous blood per protocol.

          4. Male or non-pregnant female, &gt;/= to 18 years of age at time of enrollment.

          5. Body Mass Index (BMI) 18.0-35.0 kg/m^2, inclusive (&lt; 56 years of age), at screening;
             BMI 18.0-30.0 kg/m^2, inclusive (&gt;/= 56 years of age), at screening.

          6. Women of childbearing potential* must agree to use or have practiced true abstinence**
             or use at least one acceptable primary form of contraception.***, **** Note: These
             criteria are applicable to females in a heterosexual relationship and child-bearing
             potential (i.e., the criteria do not apply to subjects in a same sex relationship).

               -  Not of childbearing potential - post-menopausal females (defined as having a
                  history of amenorrhea for at least one year) or a documented status as being
                  surgically sterile (hysterectomy, bilateral oophorectomy, tubal
                  ligation/salpingectomy, or Essure(R) placement).

                    -  True abstinence is 100% of time no sexual intercourse (male's penis enters
                       the female's vagina). (Periodic abstinence [e.g., calendar, ovulation,
                       symptothermal, post-ovulation methods] and withdrawal are not acceptable
                       methods of contraception).

                         -  Acceptable forms of primary contraception include monogamous
                            relationship with a vasectomized partner who has been vasectomized for
                            180 days or more prior to the subject's first vaccination, intrauterine
                            devices, birth control pills, and injectable/implantable/insertable
                            hormonal birth control products.

                              -  Must use at least one acceptable primary form of contraception for
                                 at least 30 days prior to the first vaccination and at least one
                                 acceptable primary form of contraception for 60 days after the
                                 last vaccination.

          7. Women of childbearing potential must have a negative urine or serum pregnancy test
             within 24 hours prior to each vaccination.

          8. Male subjects of childbearing potential*: use of condoms to ensure effective
             contraception with a female partner of childbearing potential from first vaccination
             until 60 days after the last vaccination.

             *Biological males who are post-pubertal and considered fertile until permanently
             sterile by bilateral orchiectomy or vasectomy.

          9. Male subjects agree to refrain from sperm donation from the time of first vaccination
             until 60 days after the last vaccination.

         10. In good health.*

             *As determined by medical history and physical examination to evaluate acute or
             ongoing chronic medical diagnoses/conditions that have been present for at least 90
             days, which would affect the assessment of safety of subjects. Chronic medical
             diagnoses/conditions should be stable for the last 60 days (no hospitalizations,
             emergency room (ER), or urgent care for condition or need for supplemental oxygen).
             This includes no change in chronic prescription medication, dose, or frequency as a
             result of deterioration of the chronic medical diagnosis/condition in the 60 days
             before enrollment. Any prescription change that is due to change of health care
             provider, insurance company, etc., or done for financial reasons, and in the same
             class of medication, will not be considered a deviation of this inclusion criterion.
             Any change in prescription medication due to improvement of a disease outcome, as
             determined by the participating site principal investigator (PI) or appropriate
             sub-investigator, will not be considered a deviation of this inclusion criterion.
             Subjects may be on chronic or as needed (prn) medications if, in the opinion of the
             participating site PI or appropriate sub-investigator, they pose no additional risk to
             subject safety or assessment of reactogenicity and immunogenicity, and do not indicate
             a worsening of medical diagnosis/condition. Similarly, medication changes subsequent
             to enrollment and study vaccination are acceptable provided the change was not
             precipitated by deterioration in the chronic medical condition, and there is no
             anticipated additional risk to the subject or interference with the evaluation of
             responses to study vaccination.

         11. Oral temperature is less than 100.0 degrees Fahrenheit (37.8 degrees Celsius).

         12. Pulse no greater than 100 beats per minute.

         13. Systolic blood pressure (BP) is 85 to 150 mm Hg, inclusive.

         14. Clinical screening laboratory evaluations (white blood cell (WBC), hemoglobin (Hgb),
             platelets (PLTs), alanine transaminase (ALT), aspartate transaminase (AST), creatinine
             (Cr), alkaline phosphatase (ALP), total bilirubin (T. Bili), Lipase, prothrombin time
             (PT), and partial thromboplastin time (PTT)) are within acceptable normal reference
             ranges at the clinical laboratory being used.

         15. Must agree to have samples stored for secondary research.

         16. Agrees to adhere to Lifestyle Considerations throughout study duration.

         17. Must agree to refrain from donating blood or plasma during the study (outside of this
             study).

        Leukapheresis Inclusion Criteria:

        A subject must meet all of the following criteria to be eligible for leukapheresis:

          1. Written informed consent for leukapheresis is provided.

          2. Weight &gt;/= 110 pounds.

          3. Screening laboratory evaluations are within acceptable ranges at the site where the
             leukapheresis procedure will be performed.

          4. Negative urine or serum pregnancy test within 48 hours of the leukapheresis procedure
             for women of childbearing potential.

          5. Adequate bilateral antecubital venous access.

          6. No use of blood thinners, aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) at
             least 5 days before the leukapheresis procedure.

          7. Enrolled in cohorts 2, 3, 5, 10, or 11, and possibly cohort 6, if enrolled, and
             completed the two-dose vaccination series.

        Exclusion Criteria:

        A subject who meets any of the following criteria will be excluded from participation in
        this study:

          1. Positive pregnancy test either at screening or just prior to each vaccine
             administration.

          2. Female subject who is breastfeeding or plans to breastfeed from the time of the first
             vaccination through 60 days after the last vaccination.

          3. Has any medical disease or condition that, in the opinion of the participating site
             principal investigator (PI) or appropriate sub-investigator, precludes study
             participation.*

             *Including acute, subacute, intermittent or chronic medical disease or condition that
             would place the subject at an unacceptable risk of injury, render the subject unable
             to meet the requirements of the protocol, or may interfere with the evaluation of
             responses or the subject's successful completion of this trial.

          4. Presence of self-reported or medically documented significant medical or psychiatric
             condition(s).*

             *Significant medical or psychiatric conditions include but are not limited to:
             Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma)
             requiring daily medications currently or any treatment of respiratory disease
             exacerbations (e.g., asthma exacerbation) in the last 5 years. Asthma medications:
             inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long and
             short acting beta agonists, theophylline, ipratropium, biologics.

             Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy,
             ischemic heart disease), history of myocarditis or pericarditis as an adult,
             myocardial infarction (MI) within past 6 months, coronary artery bypass surgery or
             stent placement, or uncontrolled cardiac arrhythmia.

             Neurological or neurodevelopmental conditions (e.g., history of migraines in the past
             5 years, epilepsy, stroke, seizures in the last 3 years, encephalopathy, focal
             neurologic deficits, Guillain-Barr√© syndrome, encephalomyelitis, transverse myelitis,
             stroke or transient ischemic attack, multiple sclerosis, Parkinson's disease,
             amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, or Alzheimer's disease).

             Ongoing malignancy or recent diagnosis of malignancy in the last five years excluding
             basal cell and squamous cell carcinoma of the skin, which are allowed.

             An autoimmune disease, including hypothyroidism without a defined non-autoimmune
             cause, localized or history of psoriasis.

             An immunodeficiency of any cause. Chronic kidney disease, estimated glomerular
             filtration rate (eGFR) &lt;60 mL/min/1.73m^2.

          5. Has an acute illness*, as determined by the participating site PI or appropriate
             sub-investigator, with or without fever [oral temperature &gt;/= 38.0 degrees Celsius
             (100.4 degrees Fahrenheit)] within 72 hours prior to each vaccination.

             *An acute illness which is nearly resolved with only minor residual symptoms remaining
             is allowable if, in the opinion of the participating site PI or appropriate
             sub-investigator, the residual symptoms will not interfere with the ability to assess
             safety parameters as required by the protocol.

          6. Has a positive test result for hepatitis B surface antigen, hepatitis C virus
             antibody, or human immunodeficiency virus (HIV) types 1 or 2 antibodies at screening.

          7. Has participated in another investigational study involving any investigational
             product* within 60 days, or 5 half-lives, whichever is longer, before the first
             vaccine administration.

             *study drug, biologic or device

          8. Currently enrolled in or plans to participate in another clinical trial with an
             investigational agent* that will be received during the study-reporting period.**

             *Including licensed or unlicensed vaccine, drug, biologic, device, blood product, or
             medication.

             **13 months after the first vaccination.

          9. Has previously participated in an investigational study involving lipid nanoparticles
             (LNPs) (a component of the investigational vaccine assessed in this trial).

         10. Has a history of hypersensitivity or severe allergic reaction (e.g., anaphylaxis,
             generalized urticaria, angioedema, other significant reaction) to any previous
             licensed or unlicensed vaccines.

         11. Chronic use (more than 14 continuous days) of any medications that may be associated
             with impaired immune responsiveness.*

             *Including, but not limited to, systemic corticosteroids exceeding 10 mg/day of
             prednisone equivalent, allergy injections, immunoglobulin, interferon,
             immunomodulators, cytotoxic drugs, or other similar or toxic drugs during the
             preceding 6-month period prior to vaccine administration (Day 1). The use of low dose
             topical, ophthalmic, inhaled and intranasal steroid preparations will be permitted.

         12. Anticipating the need for immunosuppressive treatment within the next 6 months.

         13. Received immunoglobulins and/or any blood or blood products within the 4 months before
             the first vaccine administration or at any time during the study.

         14. Has any blood dyscrasias or significant disorder of coagulation.

         15. Has any chronic liver disease, including fatty liver.

         16. Has a history of alcohol abuse or other recreational drug (excluding cannabis) use
             within 6 months before the first vaccine administration.

         17. Has a positive test result for drugs of abuse at screening or before the first vaccine
             administration. If cannabis is the only detected drug, inclusion is permitted.

         18. Has any abnormality or permanent body art (e.g., tattoo) that would interfere with the
             ability to observe local reactions at the injection site (deltoid region).

         19. Received or plans to receive a licensed, live vaccine within 4 weeks before or after
             each vaccination.

         20. Received or plans to receive a licensed, inactivated vaccine within 2 weeks before or
             after each vaccination.

         21. Receipt of any other SARS-CoV-2 or other experimental coronavirus vaccine at any time
             prior to or during the study.

         22. Close contact of anyone known to have SARS-CoV-2 infection within 30 days prior to
             vaccine administration.

         23. History of COVID-19 diagnosis.

         24. On current treatment with investigational agents for prophylaxis of COVID-19.

         25. Current use of any prescription or over-the-counter medications within 7 days prior to
             vaccination, unless approved by the investigator or necessary to manage a chronic
             condition.

         26. Plan to travel outside the United States (US) (continental US, Hawaii, and Alaska)
             from enrollment through 28 days after the second vaccination.

         27. Reside in a nursing home or other skilled nursing facility or have a requirement for
             skilled nursing care.

         28. Non-ambulatory.

         29. For subjects &gt;/= 56 years of age, history of chronic smoking within the prior year.

         30. For subjects &gt;/= 56 years of age, current smoking or vaping.

         31. For subjects &gt;/= 56 years of age, individuals currently working with high risk of
             exposure to SARS-CoV-2 (e.g., active health care workers with direct patient contact,
             emergency response personnel).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emory Vaccine Center - The Hope Clinic</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030-1705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101-1466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 26, 2020</verification_date>
  <study_first_submitted>February 21, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>2019-nCoV (mRNA-1273)</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Dose-escalation</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>novel coronavirus</keyword>
  <keyword>Safety</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>vaccine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

